By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat, such as the gut and respiratory system, and prevents the transmission and growth of pathogens that cause disease.
In comparison to intramuscular injections which generate systemic immunity (individuals become infected before blood-borne immunity can take effect), the oral vaccine approach prevents infections from taking hold in the body by counteracting them at the point of entry.
EncOVac, a consortium led by Poolbeg Pharma, is funded under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’) to develop a Phase I clinical trial ready oral vaccine candidate.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
